George Clark Biography and Net Worth

CAO of Biohaven

George has over 10 years of experience in the areas of SEC reporting, accounting advisory, internal controls, and corporate finance. He joined Biohaven from KPMG, LLP where he was a Senior Manager in the Hartford Audit Practice, leading various audits for one of the firm’s largest clients. Prior to KPMG, George held positions in the finance group at The Hartford Financial Services Group, Inc. and began his career at PricewaterhouseCoopers, LLP in the Hartford Assurance and Advisory Practices. George is a graduate of the University of Connecticut where he earned Bachelor and Master of Science degrees in Accounting and is a Certified Public Accountant.

What is George C. Clark's net worth?: The estimated net worth of George C. Clark is at least $146,380.65 as of May 10th, 2022. Mr. Clark owns 4,065 shares of Biohaven stock worth more than $146,381 as of December 30th. This net worth approximation does not reflect any other assets that Mr. Clark may own. Learn More about George C. Clark's net worth.
How old is George C. Clark?: Mr. Clark is currently 40 years old. There are 5 older executives and no younger executives at Biohaven. The oldest executive at Biohaven is Mr. Matthew Buten, Chief Financial Officer, who is 63 years old. Learn More on George C. Clark's age.
How do I contact George C. Clark?: The corporate mailing address for Mr. Clark and other Biohaven executives is 215 CHURCH STREET, NEW HAVEN CT, 06510. Biohaven can also be reached via phone at 203-404-0410 and via email at [email protected]. Learn More on George C. Clark's contact information.
Has George C. Clark been buying or selling shares of Biohaven?: George C. Clark has not been actively trading shares of Biohaven within the last three months. Most recently, George C. Clark sold 4,200 shares of the business's stock in a transaction on Tuesday, May 10th. The shares were sold at an average price of $141.50, for a transaction totalling $594,300.00. Following the completion of the sale, the chief accounting officer now directly owns 4,065 shares of the company's stock, valued at $575,197.50. Learn More on George C. Clark's trading history.
Who are Biohaven's active insiders?: Biohaven's insider roster includes Irina Antonijevic (Director), Gregory Bailey (Director), Robert Berman (Insider), Matthew Buten (CFO), John Childs (Director), George Clark (CAO), Vlad Coric (CEO), Declan Doogan (Director), James Engelhart (CFO), Kimberly Gentile (SVP), Julia Gregory (Director), William Jones, Jr. (Insider), Elyse Stock (Insider), and John Tilton (Insider). Learn More on Biohaven's active insiders.
Are insiders buying or selling shares of Biohaven?: In the last twelve months, Biohaven insiders bought shares 8 times. They purchased a total of 307,186 shares worth more than $12,231,711.54. The most recent insider tranaction occured on October, 2nd when Director John W Childs bought 21,052 shares worth more than $999,970.00. Insiders at Biohaven own 16.0% of the company. Learn More about insider trades at Biohaven.
Information on this page was last updated on 10/2/2024.

George C. Clark Insider Trading History at Biohaven

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/10/2022	Sell	4,200	$141.50	$594,300.00	4,065
1/19/2022	Sell	9,375	$117.01	$1,096,968.75
12/20/2021	Sell	1,915	$123.84	$237,153.60

George C. Clark Buying and Selling Activity at Biohaven

Biohaven Company Overview

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Today's Range

Now: $36.01

$35.25

$36.66

50 Day Range

MA: $45.63

$35.34

$53.69

2 Week Range

Now: $36.01

$26.80

$62.21

Volume

230,707 shs

Average Volume

1,121,759 shs

Market Capitalization

$3.64 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.24

Elon Spotted at Weird Facility in Memphis?

From Paradigm Press | Ad

What Elon Musk is planning at a remote facility in Memphis may be his greatest achievement to date. Because now, he is targeting the world’s most powerful technology… And doing it bigger – and better – than everyone else.

Go here to see what Elon is planning.

George Clark Biography and Net Worth

What is George C. Clark's net worth?

How old is George C. Clark?

How do I contact George C. Clark?

Has George C. Clark been buying or selling shares of Biohaven?

Who are Biohaven's active insiders?

Are insiders buying or selling shares of Biohaven?